Medidata’s acquisition of MC10’s digital biomarker business places the company in close competition with Evidation, Verily, and other companies offering wearable sensors and digital technologies to identify novel biomarkers in clinical trials.
In June 2019, French company Dassault Systemes, which provides software to transportation, aerospace, and life sciences companies, acquired Medidata, a provider of AI-enabled cloud-based software that helps medical devices, diagnostics, and pharmaceutical companies manage and analyze clinical trials, for an enterprise value of $5.8 billion. Medidata’s revenues for fiscal 2018 were $636 million.
Medidata, now a subsidiary of Dassault Systèmes, said the acquisition would add biometric data and additional analytics capabilities to its Patient Cloud platform, particularly to benefit patient-reported outcomes, clinical outcome assessments, and novel biomarker discovery.
“We are looking forward to moving ahead together, accelerating the development and deployment of new innovative offerings for our customers and ultimately transforming therapy development to improve the lives of patients,” said Ben Schlatka, co-founder, and CEO, MC10.
The acquisition will also enhance Medidata’s capabilities of integrating data from wearable sensors – including clinical grade metrics – to help customers successfully virtualize clinical trials, the company said.
“Medidata is excited to add the pioneering work at MC10 to our ongoing efforts in building a new platform for ingestion and analytics across a wide array of mobile sensors,” said Anthony Costello, senior vice president, Mobile Health, Medidata. “Incorporating remote biometric data capture and analysis that includes the MC10 nPoint Biostamp, alongside other leading mobile devices, will further strengthen the Medidata platform and help propel the digital transformation of life sciences.”
A total of 132 Digital Health companies were acquired during the first nine months of 2020, according to Mercom’s latest Digital Health Funding and M&A report.
Learn more about digital health M&A activity.